• About us
• Contact

Advertisement

Organisation › Details

Sanofi-Aventis S.A. (EURONEXT: SAN, NYSE: SNY)

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY). *

 

	Start	2004-12-31 merged
	End	2011-05-06 renamed
	Group	Sanofi (Group) [since May 2011]
	Today	Sanofi S.A. (Euronext: SAN, Nasdaq: SNY)
	Predecessor	Aventis (Group)
	Successor	Sanofi S.A. (Euronext: SAN, Nasdaq: SNY)
	Industry	pharmaceutical
	Region	Paris
	Country	France
	Street	174 avenue de France
	City	75013 Paris
	Tel	+33-1-5377-4000
		Address record changed: 2020-12-02
Basic data	Employees	I: 50,001 to 100,0 (2005-12-31)
	Currency	EUR
	Annual sales	28,052,000,000 (sales, net, consolidated (2007) 2007-12-31)
	Profit	5,911,000,000 (2007-12-31)
	Cash	1,711,000,000 (2007-12-31)
		* Document for »About Section«:
		Record changed: 2024-02-12

Advertisement

More documents for Sanofi (Group) [since May 2011]

• [1] Owkin. (3/21/24). "Press Release: Owkin Expands Collaboration with Sanofi Leveraging AI for Drug Positioning in immunology"....
• [2] GenSight Biologics S.A.. (12/22/23). "Press Release: GenSight Biologics Appoints Laurence Rodriguez as Chief Executive Officer". Paris....
• [3] Sanofi S.A.. (12/11/23). "Press Release: Statement on FTC Challenge to Proposed License Agreement with Maze Therapeutics". Paris....
• [4] MeiraGTx Holdings plc. (10/30/23). "Press Release: MeiraGTx Announces $30 Million Strategic Investment from Sanofi; Company Pursuing Multiple Additional Strategic Opportunities". London & New York, NY....
• [5] Sanofi S.A.. (10/3/23). "Press Release: Sanofi Announces Agreement for Potential First-in-Class Vaccine against Extraintestinal Pathogenic E. coli". Paris....
• [6] Sanofi S.A.. (3/13/23). "Press Release: Sanofi to Acquire Provention Bio, Adding to Portfolio TZIELD, the First Disease-modifying Treatment for the Delay of Stage 3 Type 1 Diabetes (T1D)". Paris & Red Bank, NJ....
• [7] Avilar Therapeutics, Inc.. (2/16/23). "Press Release: Avilar Therapeutics Increases Financing to $75 Million to Advance Pipeline of Novel Extracellular Protein Degraders". Waltham, MA....
• [8] Sanofi S.A.. (1/11/23). "Press Release: Sanofi Ventures Announces Multi-year Capital Commitment from Sanofi, Increasing Evergreen Fund to $750M". Paris....
• [9] CureVac N.V.. (1/10/23). "Press Release: CureVac Appoints Alexander Zehnder as CEO from April 1, 2023". Mainz & London....
• [10] Insilico Medicine. (11/8/22). "Press Release: Insilico Medicine Signs Strategic Research Collaboration with Sanofi Worth up to $1.2 Billion". New York, NY....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.